Bionano Genomics (BNGO) Short term Debt (2017 - 2023)

Bionano Genomics has disclosed Short term Debt across 5 years of filings, most recently posting $10.0 million for Q3 2023.

• Short term Debt for Q3 2023 came in at $10.0 million, up 7.49% year-over-year; the trailing twelve-month figure through Sep 2023 was $10.0 million (up 7.49% YoY), and the FY2022 annual result was $9.4 million, changed N/A from the prior year.
• Short term Debt came in at $10.0 million for Q3 2023 at Bionano Genomics, roughly flat from $10.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $20.1 million in Q4 2019 to a low of $799815.0 in Q2 2019.
• The 4-year median for Short term Debt is $9.7 million (2023), against an average of $10.4 million.
• Across the five-year window, Short term Debt surged 1642.65% in 2020 and climbed 7.49% in 2023, its largest moves.
• Bionano Genomics' Short term Debt stood at $20.1 million in 2019, then slipped by 29.11% to $14.2 million in 2020, then plunged by 34.11% to $9.4 million in 2022, then grew by 6.59% to $10.0 million in 2023.
• The last three Short term Debt figures came in at $10.0 million (Q3 2023), $10.0 million (Q2 2023), and $9.5 million (Q1 2023), per Business Quant data.